Correction: Progress in the discovery and development of anticancer agents from marine cyanobacteria
Hendrik Luesch, Emma K. Ellis, Qi-Yin Chen, Ranjala Ratnayake
TL;DR
This paper corrects a previously published review on anticancer agents derived from marine cyanobacteria.
Contribution
The paper provides corrections to the original article for accuracy and completeness.
Findings
Errors in the original manuscript have been identified and addressed.
Revisions ensure the scientific integrity and reliability of the information presented.
Abstract
Correction for ‘Progress in the discovery and development of anticancer agents from marine cyanobacteria’ by Hendrik Luesch et al., Nat. Prod. Rep., 2025, 42, 208–256, https://doi.org/10.1039/D4NP00019F.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2- —National Cancer Institute10.13039/100000054
- —National Institute of General Medical Sciences10.13039/100000057
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsMicrobial Natural Products and Biosynthesis · Cancer Research and Treatments · Microbial Metabolism and Applications
The authors regret that are errors in the structures shown in Fig. 2 and Fig. 4 of the published article. The changes made and the corrected figures can be found here.
In Fig. 2 the MMAF-based ADC is now depicted separately from MMAE-based ADCs because the linker is shorter compared with MMAE-based ADCs. The caption for Fig. 2 as included in the original article and here was correct at the time of publication. However, the authors would like to note that the MMAF-based ADC (Blenrep) has since been approved for clinical use.
In Fig. 4 the propyl carbon chain between dolastatin 15 and the maleimido group of compound 27a has been updated to an ethyl carbon chain.
The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.